Registration successful
Account activated – pending validation.
Your account has been activated successfully, but we still need to validate you as a healthcare professional. We’ll send you an email with the result of the validation process in the next [five] days.
In the meantime, you can enjoy access to all the latest news, events and resources on our website
Defining asthma control
How do patient perceptions of asthma control differ from guideline definitions?
The Salford Lung Study (SLS) was a robust, open-label, pragmatic RCT comparing Relvar with usual care (ICS or ICS/LABA) in 4233 patients.1
Improvement seen in everyday practice1
At baseline, the most commonly prescribed ICS/LABAs were:2
- Fluticasone propionate/salmeterol
- Budesonide/formoterol
- Beclomethasone/formoterol
This graph has been independently created by GSK from the original data. The same results were first published in Woodcock A, et al. Lancet 2017;390:2247–2255.
Relvar – studied in an RCT in everyday practice1
Proactive asthma control with Relvar improves symptoms vs other ICS/LABAs4
Looking at the individual aspects of the Asthma Control Test (ACT), Relvar treatment provides a higher mean change in symptom improvement from baseline vs other commonly prescribed ICS/LABAs.‡4
This graph has been independently created by GSK from the original data. The same results were first published in Svedsater H, et al. Respir Med 2018;141:198–206.
What does this all mean for asthma patients?
With more patients achieving asthma control1 and experiencing improved symptoms4 vs other ICS/LABAs, prescribing Relvar to patients like Oscar and Paula may mean they can get back to their normal lives.5,6
Fluticasone furoate and vilanterol are not licensed as monotherapies in asthma in all markets. Hypothetical patient used for illustrative purposes only.
Fluticasone furoate and vilanterol are not licensed as monotherapies in asthma in all markets. Hypothetical patient used for illustrative purposes only.
Good symptom control and exacerbations
Good symptom control is strongly associated with reduced risk of exacerbations.6
See what effect Relvar has on exacerbation risk.
Discover Relvar
Need help with this product?
Footnotes
*The primary endpoint was the proportion of patients who achieved an improvement in ACT score from baseline of ≥3 or a total ACT score of ≥20, in patients in the PEA population initiated on Relvar vs continuing on usual care (ICS or ICS/LABA) at 24 weeks. The primary endpoint was met (p<0.0001). Data presented are from a subset of patients prescribed ICS/LABA at baseline who were initiated on Relvar or continued on their ICS/LABA. Data showed a relative difference of 25% and an absolute difference of 14%.1 In this study there was no difference in serious adverse events reported between Relvar and usual care. The most common serious adverse events of special interest were cardiovascular disease, asthma and bronchospasm, and pneumonia.1
†Often excluded from traditional RCTs.
‡Statistical analysis was not performed on the individual questions of the ACT. Data presented are from a pre-planned analysis from a subset of patients in the ITT population prescribed ICS/LABA at baseline initiated with Relvar or continued on their existing ICS/LABA. Overall mean change in ACT score from baseline was 3.3 for Relvar and 1.8 for ICS/LABAs (p<0.001).3
§Baseline was measured as at least one night of symptoms in the last week of the run-in period, in patients who were uncontrolled on ICS with/without LABA.
Abbreviations
ACT, Asthma Control Test; CI, confidence interval; FF, fluticasone furoate; FP, fluticasone propionate; GINA, Global Initiative for Asthma; ICS, inhaled corticosteroid; ITT, intention-totreat; LABA, long-acting β2-agonist; OR, odds ratio; PEA, primary effectiveness analysis; RCT, randomised controlled trial; SLS, Salford Lung Study.
References
- Woodcock A, et al. Lancet 2017;390:2247–2255.
- GSK clinical study report. HZA115150; 2017. Accessed June 2023.
- Herland K, et al. Respir Med 2005;99:11–19.
- Svedsater H, et al. Respir Med 2018;141:198–206.
- Kerwin E, et al. J Asthma 2018;55:890–897.
- GINA. Global strategy for asthma management and prevention, 2020. Available at: www.ginasthma.org. Accessed June 2023.
RELVAR Ellipta was created in collaboration with
Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: www.hpra.ie. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.
Relvar is a registered trademark of the GlaxoSmithKline group of companies
PM-IE-FFV-WCNT-230007 June 2023
